Quick Summary
- Law 5 of the Tony Huge Laws of Biochemistry Physics: compounds hitting different receptor systems stack additively. Compounds hitting the same receptor stack with diminishing returns.
- The math is the parallel-vs-series circuit analogy. Parallel pathways add current. Series compounds compete for the same throughput.
- Independent receptor stacking is why testosterone + GH + a peptide each produces compounded results, while three different SARMs largely waste each other.
- The protocol question is not “which compound is strongest” but “which combination hits the most independent pathways toward my outcome.”
- The Natural Plus angle: map your stack to receptor categories. If two compounds share a target, drop one. If they hit different pathways, keep both.
Most stack design is bad because most stack design ignores receptor biology. People pick compounds based on what they read worked for someone else, layer them together, and hope for additive effects. Sometimes they get it. More often they get redundancy, side-effect compounding without performance compounding, and an expensive protocol that underperforms a cleaner one.
Law 5 of the Tony Huge Laws of Biochemistry Physics is the rule that fixes this: compounds hitting independent receptor systems stack additively. Compounds hitting the same receptor saturate and waste each other.
The Physics Analogy
Batteries in parallel add current without raising voltage. Each battery contributes its own output through its own circuit. Batteries in series share the same circuit — voltage adds but current is limited by the weakest cell.
Independent receptor systems are parallel batteries. The androgen receptor, the GH receptor, the ghrelin receptor, the GLP-1 receptor, and the follistatin pathway all operate on different signaling circuits. Activating each one adds its own current toward the outcome. No interference.
Compounds targeting the same receptor are series cells. Adding a second testosterone ester to a testosterone protocol does not double the androgen receptor signal. The receptor is already saturated at the doses that matter. You added milligrams without adding biology.
The Receptor Map For Body Composition
For body recomposition and performance, the major independent receptor systems are:
- Androgen receptor (AR): testosterone, DHT, nandrolone, SARMs.
- GH receptor / IGF-1 axis: exogenous GH, GHRH analogs (sermorelin, tesamorelin, CJC-1295), GHRP-class secretagogues, MK-677.
- Ghrelin receptor: MK-677, ipamorelin, GHRP-2, GHRP-6.
- Follistatin / myostatin pathway: follistatin-344, YK-11, epicatechin.
- Insulin / IGF receptor: insulin, IGF-1 LR3, metformin (sensitizer), berberine (sensitizer).
- Beta-adrenergic receptor: clenbuterol, salbutamol, yohimbine.
- GLP-1 / GIP / glucagon: semaglutide, tirzepatide, retatrutide.
- Thyroid receptor: T3, T2.
Reading The Stack For Redundancy
Take any proposed stack and tag each compound by receptor target. If you see two compounds in the same row, you almost certainly have redundancy. Drop the weaker one or rotate them in alternating cycles.
Example 1: Redundant stack. Testosterone + nandrolone + LGD-4033. Three AR ligands. The AR is saturated by the first one. The second and third add side effects without proportional benefit.
Example 2: Independent stack. Testosterone + tesamorelin + MK-677 + retatrutide. AR + GH/IGF axis + ghrelin receptor + GLP-1/GIP/glucagon. Four independent pathways. Each contributes its own current. The stack does what no single compound at any dose could do.
Example 3: Overlapping but acceptable. Tesamorelin + ipamorelin. Both hit the GH axis, but at different points (GHRH analog vs ghrelin agonist). The combination produces a larger GH pulse than either alone because they activate sequential steps. Acceptable redundancy when the steps are distinct.
The Diagnostic Framework For Stack Design
- Define the outcome. Fat loss? Hypertrophy? Cognitive performance? Each has its own receptor map.
- List the receptor systems that drive that outcome. For fat loss: GLP-1/GIP/glucagon, beta-adrenergic, thyroid, GH/IGF. For hypertrophy: AR, GH/IGF, follistatin, insulin.
- Pick one compound per receptor system. The strongest, the most cost-effective, or the one with the best side-effect profile.
- Stack across systems, not within. The total cost should be lower than people typically run because you are not paying for redundant AR ligands.
- Validate via bloodwork. Each compound should produce measurable evidence at its specific marker. Testosterone elevates total T. GH protocols elevate IGF-1. GLP-1 changes glucose-insulin dynamics. If your bloodwork doesn’t move, you missed.
Five Stacking Examples That Apply Law 5
Fat loss recomp: Retatrutide microdose + tesamorelin + low-dose T3 + L-carnitine. Hits GLP-1/GIP/glucagon, GH axis, thyroid receptor, and mitochondrial fatty acid transport. Four independent pathways toward fat oxidation.
Hypertrophy with safety: Testosterone replacement + follistatin or YK-11 + MK-677 + insulin sensitivity stack (berberine, metformin). Hits AR + myostatin inhibition + GH/ghrelin axis + insulin sensitivity. Independent pathways toward muscle gain without piling on AR ligands.
Recovery and tissue repair: BPC-157 + TB-500 + CJC-1295 + NAD+ depot. Hits regenerative tissue signaling + actin sequestration + GH axis + sirtuin/mitochondrial pathway.
Cognitive performance: Selank + Semax + Lions Mane + a racetam. Hits BDNF/neurotrophic + dopaminergic/cholinergic + NGF + AMPA modulation. Four independent neurochemical systems.
Longevity: Rapamycin (pulsed) + NAD+ + senolytic + spermidine. mTOR suppression + sirtuin activation + senescent cell clearance + autophagy activation. Four hallmarks of aging hit by four independent mechanisms.
Stacking Recommendations By Outcome
- Hypertrophy: See testosterone optimization, MK-677, and follistatin-344.
- Fat loss: See GLP-1 anti-aging stack and tesamorelin.
- Recovery: See BPC-157 and TB-500.
- Longevity: See rapamycin and senolytics.
Target Audience
Law 5 applies most to: anyone running 3+ compounds simultaneously, anyone whose stack has grown by accident over time, anyone whose results don’t match the cost or risk of their protocol, and anyone designing a new protocol from scratch.
Timeline / Results
| Audit Step | What You Do |
|---|---|
| Today | List every compound. Tag each by receptor target. |
| Week 1 | Cut redundant compounds. Adjust dose if needed. |
| Week 4 | Reassess output. Add or swap if a receptor system is unaddressed. |
| Week 8-12 | Bloodwork. Confirm each receptor target is moving the expected marker. |
Interesting Perspectives
The most overlooked implication of Law 5 is the cost compression effect. A receptor-mapped stack is almost always cheaper than the over-stuffed protocol it replaces, because you stop paying for redundant compounds. The user who drops the second AR ligand and adds a GH-axis compound spends the same money for substantially more output. The leverage is not in budget — it is in which pathways you cover.
Contrarian take: the “more is more” stack culture in performance circles is a Law 5 violation at scale. Three SARMs, two AAS, two ancillaries, and a GH peptide will produce less hypertrophy per dollar and per side-effect than a single TRT dose, follistatin, MK-677, and dialed insulin sensitivity. The entire enhanced bodybuilding ecosystem has been collectively learning this for ten years and the message still hasn’t penetrated.
Cross-domain connection: Law 5 is identical to the diversification principle in portfolio theory. Correlated assets (same receptor) do not reduce risk or increase return. Uncorrelated assets (independent receptors) compound. The Sharpe ratio of a stack — output per unit side-effect risk — is maximized by independent receptor diversification.
The hypocrisy angle: the same population that lectures bodybuilders about polypharmacy will take five different psychiatric medications targeting different receptor classes (SSRI + atypical antipsychotic + benzodiazepine + stimulant + mood stabilizer) and call it good medicine. The principle is identical. Independent receptor stacking is what works. The framing depends on who is doing it.
FAQ
What is Tony Huge Law 5 of Biochemistry Physics? Compounds hitting independent receptor systems stack additively. Compounds hitting the same receptor saturate and waste each other.
How do I know if my stack has redundancy? Tag each compound by receptor target. If two compounds share a target, you have redundancy.
Why does adding a second AR ligand not double my gains? The androgen receptor saturates at the doses that matter. The second compound adds milligrams and side effects without adding receptor signal.
What is the simplest independent stack for body recomposition? Testosterone + tesamorelin + MK-677 + retatrutide microdose. Four independent pathways, four different receptor systems, additive output.
How do I validate that my stack is hitting independent receptors? Bloodwork. Each receptor system should have a measurable downstream marker. If only one marker is moving, you have receptor redundancy.
Cross-Reference
For the framework overview see Tony Huge Laws of Biochemistry Physics. For receptor-mapped hypertrophy see Protocol: Hormones. For peptide stacking see peptide stacking 101. For the foundational framework see Enhanced Athlete Protocol.